CompletedNCT00373672
Official study titleEffect of Addition of Modafinil on the Tolerability and Efficacy for Cognition of Atypical Antipsychotic Drugs in Patients With Schizophrenia or Schizoaffective Disorder
This study has finished and is no longer accepting participants.
In NashvilleSchizophreniaMedication studyAges 18–65
- Countries
- United States
- Sponsor
- Northwestern University
CompletedNCT00212784
What is this study about?This study evaluated the safety and effectiveness of olanzapine for people with schizophrenia.
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaMedication studyAges 18+
- Countries
- Sponsor
- Organon and Co
CompletedNCT00212771
What is this study about?This study evaluated the safety and effectiveness of asenapine for people with schizophrenia.
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaMedication studyAges 18+
- Countries
- Sponsor
- Organon and Co
CompletedNCT00512070
Official study titleMelatonin Metabolism Abnormality in Patients With Schizophrenia or Schizoaffective Disorder Treated With Olanzapine and Melatonin Dose Finding for the Correction of the Metabolic Abnormality
This study has finished and is no longer accepting participants.
In TacomaSchizophrenia, BipolarityMedication studyAges 18–65
- Countries
- United States
- Sponsor
- Seattle Institute for Biomedical and Clinical Research
CompletedNCT06319170
Official study titleA Multi-center, Open-label, Randomized, Parallel-group Trial to Characterize the Pharmacokinetics of Three SC Olanzapine Extended-release Formulations With Different Release Rates Following Single Administration in Participants With Schizophrenia or Schizoaffective Disorder
This study has finished and is no longer accepting participants.
Multiple locations, including Los AlamitosSchizophreniaMedication studyAges 18–64
- Countries
- United States
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
CompletedNCT01490086
What is this study about?This study evaluated the safety and effectiveness of RP5063 for people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including PhiladelphiaSchizophreniaMedication studyAges 18–65
- Countries
- United States, India, Malaysia, + 2 others
- Sponsor
- Reviva Pharmaceuticals
CompletedNCT02411526
What is this study about?This study evaluated the safety of ZX003 (Risperidone-SABER®) for people with schizophrenia.
This study has finished and is no longer accepting participants.
In Long BeachSchizophreniaMedication studyAges 18–60
- Countries
- United States
- Sponsor
- Zogenix, Inc.
CompletedNCT05779241
What is this study about?This study evaluated the safety of LYN-005 for people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including Garden GroveSchizophreniaMedication studyAges 18–64
- Countries
- United States
- Sponsor
- Lyndra Inc.
RecruitingACTRN12619000559112
Official study titlePilot randomised controlled trial of two telephone delivered interventions for hazardous alcohol use among young people living with severe mental ill-health
In NewcastleSchizophreniaInterventional studyAges 16+
- Countries
- Australia
- Sponsor
- The University of Newcastle
RecruitingNCT05157620
About this title
Exercise-based Program for Rehabilitation of Veterans With Severe Mental Illness
Read the official source — NCT05157620Official study titleExercise-based Program for Rehabilitation of Veterans With Severe Mental Illness
In PittsburghSchizophrenia, BipolarityInterventional studyAges 18–70
- Countries
- United States
- Sponsor
- VA Office of Research and Development (Government agency)
RecruitingISRCTN71800376
In United KingdomSchizophreniaResearch studyAges 14+
- Countries
- United Kingdom
- Sponsor
- University of Oxford (University)
Not Yet RecruitingACTRN12624000136505
Official study titleVirtual reality based cognitive behavioural therapy for young people experiencing
hallucinations: LINK feasibility and acceptability trial
This study isn't recruiting yet.
Multiple locations, including ParkvilleSchizophreniaInterventional studyAges 16–25
- Countries
- Australia
- Sponsor
- The Royal Melbourne Hospital